Immunome (NASDAQ:IMNM) Receives Outperform Rating from Wedbush

Wedbush restated their outperform rating on shares of Immunome (NASDAQ:IMNM - Free Report) in a report published on Thursday morning,Benzinga reports. Wedbush currently has a $33.00 target price on the stock.

Several other equities research analysts have also weighed in on the stock. Guggenheim lowered their target price on shares of Immunome from $35.00 to $25.00 and set a "buy" rating on the stock in a report on Thursday. Stephens restated an "overweight" rating and issued a $30.00 price target on shares of Immunome in a research report on Thursday. Finally, Lifesci Capital began coverage on Immunome in a research report on Tuesday, March 11th. They issued an "outperform" rating and a $20.00 price objective for the company. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $25.50.

Immunome Stock Performance

Shares of IMNM stock traded down $0.03 during trading hours on Thursday, hitting $8.15. The company had a trading volume of 960,264 shares, compared to its average volume of 827,037. Immunome has a 12 month low of $8.12 and a 12 month high of $26.70. The firm's fifty day moving average is $9.72 and its 200 day moving average is $11.49. The firm has a market capitalization of $650.18 million, a price-to-earnings ratio of -1.00 and a beta of 1.93.

Remove Ads

Immunome (NASDAQ:IMNM - Get Free Report) last announced its quarterly earnings results on Wednesday, March 19th. The company reported ($0.84) EPS for the quarter, missing the consensus estimate of ($0.68) by ($0.16). Immunome had a negative net margin of 3,014.59% and a negative return on equity of 48.63%. The company had revenue of $2.74 million during the quarter, compared to analyst estimates of $3.07 million. On average, sell-side analysts expect that Immunome will post -2.21 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Clay B. Siegall bought 150,000 shares of the stock in a transaction dated Friday, January 31st. The stock was bought at an average cost of $7.75 per share, with a total value of $1,162,500.00. Following the purchase, the chief executive officer now owns 669,636 shares of the company's stock, valued at approximately $5,189,679. This represents a 28.87 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 8.60% of the company's stock.

Hedge Funds Weigh In On Immunome

Several hedge funds have recently added to or reduced their stakes in IMNM. BNP Paribas Financial Markets bought a new stake in Immunome during the 4th quarter worth about $70,000. KLP Kapitalforvaltning AS bought a new position in shares of Immunome in the 4th quarter valued at about $75,000. AlphaQuest LLC grew its position in shares of Immunome by 786,700.0% during the 4th quarter. AlphaQuest LLC now owns 7,868 shares of the company's stock worth $84,000 after buying an additional 7,867 shares during the period. Tower Research Capital LLC TRC raised its stake in shares of Immunome by 482.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 8,608 shares of the company's stock worth $91,000 after buying an additional 7,129 shares during the last quarter. Finally, Aquatic Capital Management LLC bought a new stake in shares of Immunome during the fourth quarter worth approximately $95,000. Institutional investors own 44.58% of the company's stock.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.